This receptor is emerging as an important effector of the EMT program, and its activation is responsible for triggering important oncogenic pathways, such as PI3K/AKT/mTOR, NF-κB, EGFR, and MAPK cascades, involved in cell proliferation, survival, and invasion.21–26 In line with different studies on human cancer, we found that the increased expression of AXL significantly correlated with poor outcome in TNBC.21–28 High levels of AXL were associated with reduced RFS and OS in TNBC patients treated with anthracycline–taxane-based adjuvant chemotherapy. This evidence concerns the gene MTOR and cancer.